Abstract
Frost & Sullivan's Medical Devices Financial Benchmarking and Analysis (FBA)
service presents a broad financial outline of the medical devices industry,
highlighting major market and financial trends in key growth segments. It
provides a comprehensive financial analysis of leading medical devices firms
to support the investment and financial analysis needs of decision makers in
the marketplace. The current study within the service focuses on the following
key growth sectors of the European Cardiology Devices Market:Cardiac Rhythm
Management, Interventional Cardiology, and Cardiac Surgery.
Opportunities in potential investments lie ahead in Europe for venture capitalists
There is an abundance of ideas for innovation in Europe, though the continent
lacks when it comes to commercialization of ideas into products.However,this
scenario is slowly changing.In order to make Europe more competitive and
innovation friendly, the European Medical Technology Industry Association
(Eucomed) has proposed ten recommendations in 2005 to augment medical
technology innovation in Europe.This 'innovation friendly' climate is expected
to lend support and unfold several opportunities for novel ideas and devices
thus presenting potential investment opportunities for venture capitalists.The
study aims to analyze these potential investment opportunities present in the
cardiovascular devices space and identify segments in the market that are
attractive to private equity participants, institutional investors, and trade
investors.
Cardiovascular device companies spring new interest in cardiac rhythm management
The European cardiovascular devices market is highly consolidated, being
controlled by global players such as Boston Scientific, Johnson & Johnson,
Medtronic, Sorin, and St. Jude Medical.With the acquisition of Guidant, by
Boston Scientific, the space is only condensing further.Key market
participants are constantly scouting for growth opportunities by acquiring
smaller companies to fill in their R&D product pipelines.Companies targeted
include those that develop technologies catering to an unmet need or that
convert a surgery from an inpatient to an outpatient setting.Additionally,
devices in the cardiac rhythm management specialty are also witnessing
increased interest by large cardiovascular device companies.Johnson & Johnson,
whose presence in the cardiac market so far has been confined to the segments
of interventional cardiology and cardiac surgery, is now eyeing for an
opportunity in the cardiac rhythm management space.Such aggressive acquisition
onpart of bigger companies present attractive exit opportunities to venture
capitalists in the form of a trade sale.
| 
View Cart
